(RXST) Rxsight - Overview
Stock: Adjustable Lens, Light Device, Cataract, Customizable
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 69.8% |
| Relative Tail Risk | -9.13% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.25 |
| Alpha | -95.19 |
| Character TTM | |
|---|---|
| Beta | 1.350 |
| Beta Downside | 2.214 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.66% |
| CAGR/Max DD | -0.15 |
Description: RXST Rxsight December 26, 2025
RxSight, Inc. (NASDAQ:RXST) is a commercial-stage medical-technology firm that develops, manufactures, and sells a light-adjustable intraocular lens (LAL) system for cataract surgery in the United States. The system pairs a photosensitive intraocular lens with an office-based ultraviolet (UV) delivery device, allowing surgeons to fine-tune postoperative refractive outcomes and improve uncorrected visual acuity.
Key operating metrics (as of FY 2023) include approximately $45 million in total revenue, a 28 % year-over-year growth rate driven primarily by increased adoption of premium cataract procedures, and an estimated 12 % market share in the U.S. premium IOL segment. The business is sensitive to macro-drivers such as the aging-population trend (U.S. adults 65+ projected to reach 23 % of the population by 2030), Medicare reimbursement policies for cataract surgery, and competitive pressure from other adjustable-lens technologies (e.g., AcuFocus, Alcon). The company’s pipeline assumes continued FDA clearance for expanded indications and a rollout of its LAL in additional ophthalmology practices, which would be required to sustain growth.
For a deeper, data-driven perspective on RXST’s valuation and risk profile, consult ValueRay’s dedicated analysis.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -35.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA 2.07 > 1.0 |
| NWC/Revenue: 184.1% < 20% (prev 190.9%; Δ -6.76% < -1%) |
| CFO/TA -0.06 > 3% & CFO -18.7m > Net Income -35.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.0m) vs 12m ago 2.96% < -2% |
| Gross Margin: 74.98% > 18% (prev 0.63%; Δ 7434 % > 0.5%) |
| Asset Turnover: 45.91% > 50% (prev 44.57%; Δ 1.33% > 0%) |
| Interest Coverage Ratio: -1782 > 6 (EBITDA TTM -32.7m / Interest Expense TTM 20.0k) |
Altman Z'' -15.00
| A: 0.85 (Total Current Assets 283.9m - Total Current Liabilities 22.3m) / Total Assets 308.5m |
| B: -2.11 (Retained Earnings -651.9m / Total Assets 308.5m) |
| C: -0.12 (EBIT TTM -35.6m / Avg Total Assets 309.5m) |
| D: -20.02 (Book Value of Equity -651.8m / Total Liabilities 32.6m) |
| Altman-Z'' Score: -23.12 = D |
Beneish M -3.03
| DSRI: 0.93 (Receivables 24.2m/25.4m, Revenue 142.1m/138.4m) |
| GMI: 0.85 (GM 74.98% / 63.45%) |
| AQI: 1.40 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.03 (Revenue 142.1m / 138.4m) |
| TATA: -0.06 (NI -35.7m - CFO -18.7m) / TA 308.5m) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of RXST shares?
Over the past week, the price has changed by -3.45%, over one month by -16.02%, over three months by -2.56% and over the past year by -75.01%.
Is RXST a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 3
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the RXST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.4 | 23.8% |
| Analysts Target Price | 10.4 | 23.8% |
| ValueRay Target Price | 7.5 | -11.2% |
RXST Fundamental Data Overview February 04, 2026
P/S = 2.5552
P/B = 1.2977
Revenue TTM = 142.1m USD
EBIT TTM = -35.6m USD
EBITDA TTM = -32.7m USD
Long Term Debt = 11.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.29m USD (from shortTermDebt, last quarter)
Debt = 11.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.1m USD (from netDebt column, last quarter)
Enterprise Value = 147.1m USD (363.1m + Debt 11.6m - CCE 227.5m)
Interest Coverage Ratio = -1782 (Ebit TTM -35.6m / Interest Expense TTM 20.0k)
EV/FCF = -6.63x (Enterprise Value 147.1m / FCF TTM -22.2m)
FCF Yield = -15.09% (FCF TTM -22.2m / Enterprise Value 147.1m)
FCF Margin = -15.62% (FCF TTM -22.2m / Revenue TTM 142.1m)
Net Margin = -25.15% (Net Income TTM -35.7m / Revenue TTM 142.1m)
Gross Margin = 74.98% ((Revenue TTM 142.1m - Cost of Revenue TTM 35.6m) / Revenue TTM)
Gross Margin QoQ = 79.85% (prev 74.89%)
Tobins Q-Ratio = 0.48 (Enterprise Value 147.1m / Total Assets 308.5m)
Interest Expense / Debt = 0.03% (Interest Expense 4000 / Debt 11.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -28.2m (EBIT -35.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.74 (Total Current Assets 283.9m / Total Current Liabilities 22.3m)
Debt / Equity = 0.04 (Debt 11.6m / totalStockholderEquity, last quarter 276.0m)
Debt / EBITDA = 0.55 (negative EBITDA) (Net Debt -18.1m / EBITDA -32.7m)
Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -18.1m / FCF TTM -22.2m)
Total Stockholder Equity = 278.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.54% (Net Income -35.7m / Total Assets 308.5m)
RoE = -12.82% (Net Income TTM -35.7m / Total Stockholder Equity 278.6m)
RoCE = -12.28% (EBIT -35.6m / Capital Employed (Equity 278.6m + L.T.Debt 11.6m))
RoIC = -10.10% (negative operating profit) (NOPAT -28.2m / Invested Capital 278.6m)
WACC = 10.55% (E(363.1m)/V(374.6m) * Re(10.89%) + D(11.6m)/V(374.6m) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 10.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.73%
Fair Price DCF = unknown (Cash Flow -22.2m)
EPS Correlation: 92.15 | EPS CAGR: 134.1% | SUE: 2.46 | # QB: 2
Revenue Correlation: 90.64 | Revenue CAGR: 40.73% | SUE: 1.08 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.16 | Chg30d=-0.010 | Revisions Net=-2 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.53 | Chg30d=-0.036 | Revisions Net=+0 | Growth EPS=-8.0% | Growth Revenue=+1.9%